Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

317 Views

Poster Session: Clinical Trials

226 - Higher Doses of Adintrevimab, an Extended Half-Life Monoclonal Antibody, for the Treatment and Prevention of COVID-19: Preliminary Results from a Phase 1 Single Ascending-Dose Study

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Virtual

The ePoster content is available to users who are logged in.<br><br>Please click the login button at the top right corner and then come back here to use this button.

Presenting Author(s)

XP

Xia Pu, PhD

clinical pharmacologist
Invivyd, Inc.
Waltham, Massachusetts, United States

Co-Author(s)

JG

Jean Gong, PhD

Adagio Therapeutics
Waltham, Massachusetts, United States
EC

Ed Campanaro, BSN, MSHS

Adagio Therapeutics
Waltham, Massachusetts, United States
KN

Kristin Narayan, PhD

Adagio Therapeutics
Waltham, Massachusetts, United States
DG

Deepali Gupta, B.Sc

Adagio Therapeutics
Waltham, Massachusetts, United States
FE

Frank Engler, PhD

Certara
Buffalo, New York, United States
AC

Amanda Copans, PharmD

Adagio Therapeutics
Waltham, Massachusetts, United States
PS

Pete Schmidt, MD

VP Clinical Research
Adagio Therapeutics
Waltham, Massachusetts, United States